Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Symptoms patents



      
           
This page is updated frequently with new Symptoms-related patent applications. Subscribe to the Symptoms RSS feed to automatically get the update: related Symptoms RSS feeds. RSS updates for this page: Symptoms RSS RSS



Date/App# patent app List of recent Symptoms-related patents
08/20/15
20150232474 
 Bicyclic substituted pyrimidine compounds patent thumbnailBicyclic substituted pyrimidine compounds
Disclosed are bicyclic group substituted pyrimidine compounds, pharmaceutical acceptable salts thereof or stereoisomers thereof. Also disclosed are preparation methods, pharmaceutical formulations, and pharmaceutical compositions of the compounds, and use of the compounds, pharmaceutical formulations, and pharmaceutical compositions for preparing a medicament for treating and/or preventing sexual dysfunction diseases and diseases with lower urinary tract symptoms..
Xuanzhu Pharma Co., Ltd.


08/20/15
20150231147 
 Methods for acute and long-term treatment of drug addiction patent thumbnailMethods for acute and long-term treatment of drug addiction
This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine at a dosage that provides an average serum concentration of about 50 ng/ml to about 180 ng/ml under conditions where the qt interval prolongation does not exceed about 50 milliseconds.. .
Demerx, Inc.


08/20/15
20150231146 
 Methods for acute and long-term treatment of drug addiction patent thumbnailMethods for acute and long-term treatment of drug addiction
This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine at a dosage that provides an average serum concentration of 50 ng/ml to 180 ng/ml (auc/24 h) under conditions where the qt interval prolongation does not exceed about 50 milliseconds.. .
Demerx, Inc.


08/20/15
20150231145 
 Methods for acute and long-term treatment of drug addiction patent thumbnailMethods for acute and long-term treatment of drug addiction
This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine at a dosage that provides an average serum concentration of about 50 ng/ml to about 850 ng/ml (auc/24 h) under conditions where the qt interval prolongation does not exceed about 50 milliseconds.. .
Demerx, Inc.


08/13/15
20150225404 
 Pyridine derivative and medicine patent thumbnailPyridine derivative and medicine
The main purpose of the invention is to provide a novel pyridine derivative or a pharmaceutically acceptable salt thereof. Examples of the invention include a pyridine derivative represented by general formula [1], and a pharmaceutically acceptable salt thereof.
Nippon Shinyaku Co., Ltd.


07/23/15
20150203505 
 Indole carboxamide derivative patent thumbnailIndole carboxamide derivative
The present inventors have conducted studies on mt1 and/or mt2 receptor agonists, and have found that an indole carboxamide compound has an mt1 and/or mt2 receptor agonistic action, thereby completing the present invention. The indole carboxamide compound of the present invention has the mt1 and/or mt2 receptor agonistic action as well as a low cns penetration, and therefore, it can be used as an agent for preventing and/or treating urological diseases; in one embodiment, lower urinary tract symptoms; in another embodiment, urine storage symptom, in another embodiment, urinary incontinence; in a still another embodiment, stress urinary incontinence; and the like..

07/16/15
20150196575 
 Compositions and methods for treating spinocerebellar ataxia patent thumbnailCompositions and methods for treating spinocerebellar ataxia
The present invention provides intravenous compositions of trehalose for the treatment of signs and symptoms of spinocerebellar ataxia (sca).. .
Bioblast Pharma Ltd.


07/02/15
20150182576 
 Multi-carotenoids compositions and uses therefor patent thumbnailMulti-carotenoids compositions and uses therefor
Methods for ameliorating the effects of benign prostate hyperplasia (bph)-related lower urinary tract symptoms (luts) in men, comprising orally administering an effective amount of multi-carotenoids compositions. Multi-carotenoids composition for oral administration comprising about 71% by weight, of a tomato extract containing therein about 2% to 10% by weight of lycopene, about 0.25% to 2% by weight of phytoene, and about 0.2% to 2% by weight of phytofluene, and about 29% by weight, of a suitable encapsulating matrix.
Health-ever Biotech Co. Ltd


05/07/15
20150126613 
 Method for the treatment or prevention of lower urinary tract symptoms patent thumbnailMethod for the treatment or prevention of lower urinary tract symptoms
This invention concerns a method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.. .
Hormos Medical Ltd.


04/23/15
20150112716 
 Individualized healthcare management system patent thumbnailIndividualized healthcare management system
Method and system for providing individualized healthcare to a patient having a chronic disease over the internet are disclosed. The system includes at least a computer server for executing application programs where the computer server includes storage means for storing patient information in at least a database server and means for communicating with at least a patient computer and a medical provider computer.

04/16/15
20150105289 

Biomarkers for lower urinary tract symptoms (luts)


Provided herein are compositions and methods for the characterization of a subject's predisposition to developing lower urinary tract symptoms (luts). In particular, biomarkers are provided that identify the likelihood that a subject with develop luts concomitant with pelvic organ prolapse (pop), and/or the likelihood that luts will persist after surgical repair of pops..
The Regents Of The University Of Michigan


04/02/15
20150094380 

Agent for improving vesicourethral dyssynergia


This invention is directed to an ameliorating agent for a disease based on vesicourethral dyssynergia, comprising, as an active ingredient, 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexene-1-one, a salt thereof, or a solvate thereof. The disease based on vesicourethral dyssynergia is any of dysuria accompanying a lifestyle-related disease (such as diabetic dysuria), idiopathic dysuria, dysuria after pelvic surgery, dysuria accompanying spinal cord injury, dysuria accompanying spinal canal stenosis, dysuria accompanying benign prostatic hypertrophy, dysuria accompanying high-pressure voiding/high-pressure urine storage, neurogenic or nonneurogenic lower urinary tract symptoms (luts), detrusor sphincter dyssynergia, and detrusor bladder neck dyssynergia..
Taiho Pharmaceutical Co., Ltd.


03/26/15
20150086596 

Organophosphates for treating afflictions of the skin


Embodiments of the invention involve treating skin afflictions by the topical or oral use of organophosphates. By effectively reducing or eliminating the population of demodex mites in affected skin areas and areas where demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the skin afflictions than any previously described method.

02/26/15
20150057618 

Long term implant access line retention device and use


Disclosed herein is an insertion site protection device that attaches to an access device. Specifically, the invention is a retention device for access lines and needles used for long-term access of drug delivery portals and pumps used to treat patients for a variety of diseases.
Sec Medical Development, Inc.


01/15/15
20150018272 

Compositions and methods of using proislet peptides and analogs thereof


Embodiments relate to proislet peptides, preferably hip, that exhibit increased stability and efficacy, and methods of using the same to treating a pathology associated with impaired pancreatic function, including type 1 and type 2 diabetes and symptoms thereof.. .
Curedm Group Holdings, Llc


01/08/15
20150011566 

N-phenylpiperazine derivatives that are antagonists of a1a, a1d adrenoceptors and 5-ht1a receptors for the treatment of benign prostate hyperplasia, pharmaceutical compositions containing the same


The present invention provides n-phenylpiperazine derivatives for use as multiple binders and/or antagonists of α1a adrenoceptors, α1d adrenoceptors and 5-ht1a serotonin receptors. These substances are candidates to prototypes for the treatment of benign prostate hyperplasia and lower urinary tract symptoms, and are useful in pharmaceutical compositions..
UniÃo Brasiliense De EducaÇÃo E Cultura - Ubec


12/25/14
20140378467 

Role of n-2-hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury


Compositions and therapeutic uses of hepes and derivatives in the treatment of pain associated with cancers and side-effects including post-chemotherapy cognitive impairment are disclosed herein. Hepes is also used to treat neurodegenerative and neurological diseases, demyelinization injuries, and side-effects and withdrawal symptoms associated with benzodiazepines, anti-depressants, and other neurological agents..
North Texas Medical Associates


11/27/14
20140350105 

Compositions and methods for producing elevated and sustained ketosis


Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/l), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time.

11/27/14
20140349980 

Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage


The present invention refers to the treatment of a patient suffering from rheumatoid arthritis by showing a reduction in signs and symptoms, a major or complete clinical response (remission) or even prevention of structural damages to the joints by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.. .

11/13/14
20140336145 

Compositions and methods for treating oculopharyngeal muscular dystrophy


The present invention provides intravenous compositions of trehalose for the treatment of signs and symptoms of oculopharyngeal muscular dystrophy (opmd).. .

11/06/14
20140328855 

Method of treating ankylosing spondylitis


The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (as). The invention describes methods and uses for treating ankylosing spondylitis, wherein a tnfα inhibitor, such as a human tnfα antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a subject.

10/30/14
20140322363 

Treatment of withdrawal symptoms to aid in nicotine use cessation with passiflora incarnata


The present invention relates to the treatment of withdrawal and craving symptoms as an aid in smoking cessation by administration of one or more dosages of a medication containing passiflora incarnata.. .

10/16/14
20140309226 

Piperidinyl-substituted cyclic ureas as gpr119 modulators


Compounds of formula i: and pharmaceutically acceptable salts thereof, in which x1, x2, r3, r4, r5, rx, r7, r9, r10 and n have the meanings given in the specification, are modulators of gpr119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.. .

10/16/14
20140308306 

Compositions and methods for treatment of kidney diseases


The invention provides compositions comprising immunogenic fragments of apob-100 for eliciting an immune response in a subject or vaccinating a subject, so as to treat, prevent, 5 inhibit and/or reduce symptoms of kidney diseases in the subject. The compositions include immunogenic fragments of apob-100, cd8+ t cells activated with immunogenic fragments of apob-100 or a combination thereof..

09/25/14
20140288063 

Heterocyclic substituted pyrimidine compound


The present invention pertains to the field of medical technology, and particularly relates to a heterocyclic substituted pyrimidine compound represented by general formula (i) and its pharmaceutically acceptable salt thereof, wherein r1, r2, r3, r4 and r5 are as defined in the description, the present invention also relates to a preparation method of the compound, a pharmaceutical composition containing the compound, and a use of the compound and the pharmaceutical composition in preparation of a medicine for enhancing a cgmp signal transduction function or a medicine for treating or preventing sexual dysfunction and diseases with lower urinary tract symptoms.. .

09/18/14
20140275839 

Devices and methods for tissue immobilization and non-invasive lower urinary tract analysis


Provided are devices and methods suitable for immobilizing tissue and for use in non-invasive methods of assessing lower urinary tract symptoms as well as in surgical application.. .

09/11/14
20140256756 

Piperidinyl-substituted lactams as gpr119 modulators


Compounds of formula (i) and pharmaceutically acceptable salts thereof in which x1, x2, x3, l, r3, r4, r5, r7 and n have the meanings given in the specification, are modulators of gpr119 and are useful in the treatment or prevention of diseases such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.. .

08/14/14
20140228362 

Method of treatment or prophylaxis


The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin ii receptor 2 (at2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of neuropathic pain, including mechanical hyperalgesia, thermal or mechanical allodynia, diabetic pain and entrapment pain, in vertebrate animals and particularly in human subjects.

04/24/14
20140114678 

Secure delivery of personalized neuromodulation treatment protocols across the internet to a stimulator device


This invention manages the variation of neuromodulation sequences inherent in effective treatment for poly-substance abuse and dependence through downloadable neuromodulation protocols for common poly-substance combinations. The substance abuse profiles and the poly-substance neuromodulation protocols are placed on an internet connected server, allowing effective management of complex treatments via network-attached client software to addiction clinics in most of the geographic areas in the world.

04/24/14
20140113970 

Dispensing system


The invention provides systems and methods for controlled dispensing of topical analgesics contained in a metered dispensing system. The systems and method are useful for treating signs and symptoms of osteoarthritis.

04/10/14
20140100241 

Drug detoxification protocol using microdosing


This invention relates to use of an opioid receptor agonist in microdose quantities to reduce or eliminate the withdrawal symptoms associated with discontinuing drug use. The dosage of the agonist is reduced over an extended period of time..

01/16/14
20140017177 

Silene capensis for inhibiting cravings


A composition can include: silene extract; and a carrier having the silene extract. The composition can include an active agent, such as a pharmaceutical or a nutraceutical.

12/26/13
20130345313 

Method for the treatment or prevention of lower urinary tract symptoms


This invention concerns a method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.. .

12/19/13
20130338116 

Compounds and methods for the treatment of pain and other diseases


The present invention relates generally to pharmaceutical agents, and in particular, to metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of dual acting mmp-2 and mmp-9 inhibiting compounds that exhibit increased potency, metabolic stability and/or reduced toxicity in relation to currently known mmp-2 and mmp-9 inhibitors for the treatment of pain and other diseases.

11/07/13
20130296350 

Method of treatment or prophylaxis


The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin ii receptor 2 (at2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of neuropathic pain, including mechanical hyperalgesia, thermal or mechanical allodynia, diabetic pain and entrapment pain, in vertebrate animals and particularly in human subjects.

10/31/13
20130287775 

Combination therapy for treatment of immune disorders


Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of il-23 is continued for a longer time to prevent recurrence of the acute event.

10/24/13
20130281390 

Method for treating dry eye


This invention relates to methods of treating dry eye disease. The methods comprise identifying a patient suffering from dry eye disease, and topically administering to the eyes of the patient an effective amount of azithromycin and an effective amount of a retinoid.

10/17/13
20130274214 

Method for treating blepharitis


This invention relates to methods of treating blepharitis. The methods comprise identifying a patient suffering from blepharitis, and topically administering to the eyes of the patient an effective amount of azithromycin and an effective amount of a retinoid.

10/10/13
20130268296 

Method and identifying, monitoring and treating medical signs and symptoms


A system for identifying and monitoring risk of a plurality of predefined mental health disorders in a single composite score is provided. The system includes a network portal providing access to at least one patient and at least one health care provider; a patient symptom inventory including a grouped, listing of questions corresponding to a plurality of mental symptoms; and a patient assessment progress record including an assessment record for tracking the patient's risk of suffering from the plurality of potential mental conditions over time.

10/10/13
20130267557 

Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent


The combined use of (r)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide (tamsulosin), or its pharmaceutically acceptable salt, and (1s)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3r)-quinuclidin-3-yl ester (solifenacin), or its pharmaceutically acceptable salt, for the preparation of a medicament for the improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia (luts/bph) with a substantial storage component is provided.. .

09/05/13
20130231312 

Treatment of type ii diabetes and diabetes-associated diseases with safe chemical mitochondrial uncouplers


This application discloses methods for treating, preventing and/or alleviating the symptoms of type ii diabetes and diabetes-related disorders or complications. The invention provides a novel approach to treating and managing disorders and symptoms related to elevated plasma glucose concentrations and insulin resistance, characterized by few side effects and low toxicity.

08/29/13
20130224172 

Methods of treating behavioral symptoms of neurological and mental disorders


Disclosed herein are methods of using coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations for treatment of subjects having behavioral disorders, neurological disorders or mental health disorders. Disclosed herein are methods of treating core and non-core symptoms of behavioral disorders, neurological disorders or mental health disorders.

08/08/13
20130204182 

Method and inserting a rectal suppository


Rectal suppositories are used to administer a predetermined drug dosage to treat a variety of diseases and symptoms in a variety of patient populations. Certain medical conditions, such as digestive disorders, may be more effectively treated when the suppository is placed in a particular location of the patient's anal canal or rectum.

07/25/13
20130190279 

Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage


The present invention refers to the treatment of a patient suffering from rheumatoid arthritis by showing a reduction in signs and symptoms, a major or complete clinical response (remission) or even prevention of structural damages to the joints by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.. .

07/18/13
20130184257 

Piperidinyl-substituted lactams as gpr119 modulators


Compounds of formula (i) and pharmaceutically acceptable salts thereof in which x1, x2, l, r3, r4, r5, r7 and n have the meanings given in the specification, are modulators of gpr119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.. .

06/20/13
20130158082 

Methods of managing blood sugar levels and compositions related thereto


The disclosure relates to methods of managing blood sugar levels and compositions related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diabetes, insulin resistance, or hyperglycemia comprising administering to a subject diagnosed with, at risk of or exhibiting symptoms of diabetes, insulin resistance, or hyperglycemia a pharmaceutical composition comprising a compound comprising formula i..

06/20/13
20130158009 

Piperidinyl-substituted lactams as gpr119 modulators


Compounds of formula (i): and pharmaceutically acceptable salts thereof in which x1, x2, l, r3, r4, r5, r6, r6a, r7, r9, r9a, and n have the meanings given in the specification, are modulators of gpr119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.. .

06/20/13
20130157990 

Method of drug detoxification


A method of detoxifying a patient addicted to at least one drug comprises the step of administering a first-medication component to the patient for mitigating drug withdrawal symptoms of the patient. The method further comprises the step of administering an anesthetic component to the patient for putting the patient in a sedated state.

05/23/13
20130131127 

Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions


Method of using dopamine reuptake inhibitors, e.g., sydnonimine derivatives, for the management of diabetic symptoms and associated complications or conditions, such as hyperglycemia and diabetic neuropathy.. .

05/16/13
20130121992 

Molecules and methods for treatment of diabetes


Described are antibodies that specifically recognize and bind the epitope of glutamate decarboxylase (gad65) that is bound by antibody b96.11, and anti-idiotypic antibodies that are capable of competing with gad65 for binding with b96.11 and competitively inhibit such binding. These antibodies can be provided in the form of a pharmaceutical composition and can be used in methods for delaying the onset of type 1 diabetes and for inhibiting insulitis and other diabetic symptoms.

05/02/13
20130109755 

Baclofen formulations and methods for making same


Methods for preparing sterilized baclofen solutions include adjusting the ph to below a desired ph, and steam sterilizing the solution with adjusted ph, which results in the solution having the desired ph. Such solutions may also have low concentrations of 4-cpp.

04/25/13
20130102919 

Model based control of parkinson's disease


The present invention relates to a novel means to use a fundamental model of the parts of the brain that are dysfunctional in parkinson's disease, and related dynamical diseases of the brain, as part of a feedback control system to modulate the signs and symptoms of disease. Fundamental computational models that embody our knowledge of the anatomy, neurons, and dynamics of the parts of the brain we wish to control, and use those models to reconstruct what is inaccessible to our measurements.

04/04/13
20130085106 

Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders


The invention provides a method of treating a psychiatric or medical disorder in a mammalian subject, the method comprising administering to the subject an effective amount of an oxytocin receptor agonist (e.g., oxytocin). Optionally, the oxytocin receptor agonist is delivered by intranasal administration.

03/28/13
20130080425 

Personalized medical treatment provision software


A method for providing information exchange and analysis to a medical knowledge database that collects, organizes, and retrieves clinical experience information sets submitted by a plurality of treatment providers and researchers. The plurality of treatment providers and researchers submit clinical information containing biological sequences, signs and symptoms, and medical assessments to the database.

02/07/13
20130034525 

Beta iselets-like cells derived from whole bone marrow


The invention provides for methods of producing pancreatic precursor cells and insulin-producing cells from bone marrow. In various embodiments, bone marrow derived stem cells are differentiated into pancreatic precursor cells and insulin-producing cells.

01/24/13
20130023575 

Compositions and methods for the treatment of ocular surface allergies


The disclosure provides ophthalmic compositions, systems and methods for the treatment of ocular surface allergies. More particularly the present invention relates to compositions of bromfenac for the treatment of the signs and symptoms of ocular surface allergies due to seasonal allergies..

01/03/13
20130004428 

Diazabicyclononyl oxadiazole compounds and their use as nicotinic acetylcholine receptor modulators


This invention relates to diazabicyclononyl oxadiazolyl derivatives, which are found to-be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (cns), the peripheral nervous system (pns), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.



Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Symptoms for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Symptoms with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.2789

3543

2 - 1 - 62